drops a 10 g weight from a height of 12.5 mm. The injured rats received either i.p. injections of FA (80 μg/kg) or water (control) 3 days prior and 17 days post-cSCI (mid phase) or for 3 days pre-cSCI and 14 days post-cSCI ending on the 42nd day of cSCI (late phase). The functional neurological deficits due to cSCI were then assessed by Basso, Beattie, and Bresnahan (BBB) scores either on post-impaction days 0 through 18 post-cSCI (mid phase) or on days 0, 2, 7, 14, 21, 28, 35, and 42 (late phase). Baseline measurements were taken the day before starting treatments. Thermal hyperalgesia (TH) testing for pain was performed on 4 days pre-cSCI (baseline data) and on days 18, 21, 28, 35, and 42 post-cSCI. Following TH testing, animals were euthanized and spinal cords harvested for MMP-2 expression analysis. Result: The FA-treated groups showed higher BBB scores during mid phase (day 18) and in late phase (day 42) of injury compared to controls, suggesting enhanced functional recovery. There is a transient decline in TH in animals from the FA-treated group compared to controls when tested on days 18, 21, 28, and 35, indicative of a decrease in NP. However, when tested 25 days after stopping FA administration on day 42 of cSCI, no significant difference in TH was observed between FA-treated and control animals. Western blot analysis of the injured spinal cord from FA-treated animals showed significant decline in MMP2 expression compared to spinal cord samples from water-treated controls. Conclusion: Together, these data suggest that FA could alleviate NP and improve functional recovery post-SCI, possibly by reducing the expression of MMP2. Further studies will open up a novel and easy natural therapy, ideal for clinical translation with minimal side effects, for managing SCI-induced NP. Such studies might also throw light on a possible epigenetic mechanism in FA-induced recovery after SCI.
Introduction
More than 1 million people suffer from spinal cord injury (SCI) in the United States alone, with an additional 12,000 new cases each year. Lack of therapeutic options for mollifying the initial mechanical destruction of tissue and the secondary factors that contribute to total tissue damage in SCI necessitate further investigations of the fundamental mechanisms of SCI-induced neuropathic pain (NP) . Recent studies have demonstrated that matrix metalloproteinase (MMPs) such as MMP2 and MMP9 play a critical role in extracellular matrix breakdown and in inducing NP following SCI [1] [2] [3] [4] [5] . It has been shown that inhibiting MMP2 and MMP9 significantly decreases NP in animals that have undergone spinal nerve ligation [1] . However, the underlying mechanisms are unknown. Studies have shown that promoter methylation suppresses the transcription of MMPs and that intrathecal administration of DNA methyl transferase inhibitor following chronic constriction injury (CCI) results in the suppression of global DNA methylation and the methyl-CpGbinding protein 2 (MeCP2) expression, both of which are correlated to a decrease in NP in injured rats [6] . In contrast, SCI results in an increase in global DNA methylation [6] . It is known that hyper methylation of the promotor can silence gene expression [7] [8] [9] [10] . In the light of these observations, we hypothesize that possible alterations in DNA methylation pathways might offer promising new therapeutic avenues to alleviate NP and promote functional recovery.
Earlier studies have shown that folic acid (FA), a dietary supplement and the key methylator of the central nervous system (CNS), induces spinal axon regeneration and improves functional recovery after SCI partly via DNA methylation [11, 12] . In this paper, we report that FA treatment after injury alters the expression of MMP2, alleviates NP, and improves functional recovery after SCI.
Methods

Animals
Adult male Sprague-Dawley rats weighing 250-270 g were obtained from Harlan Laboratories, Madison, WI, USA. The SCI and the experiments using animals were conducted with approval from the University of Wisconsin Research Animal Resources and Care Committee and in accordance with published NIH guidelines.
Chemicals
The source of the chemicals and other materials used in the study are specified wherever they are mentioned in the text.
Drug Administration
The spinal cord-injured animals were treated intraperitonially with a standardized dose of FA (80 μg/kg body weight) [11, 12] either for 3 days pre-contusion spinal cord injuries (cSCIs) and 17 days post-cSCI (mid phase) or for 3 days pre-cSCI and 14 days post-cSCI ending on the 42nd day of cSCI (late phase).
Surgery
We employed a cSCI model to analyze the effect of FA on MMP2 expression and NP.
Contusion SCI
Sprague-Dawley male rats weighing 250-270 g received cSCI with a custom spinal cord impactor device that drops a 10 g weight from a height of 12.5 mm as described earlier [13] [14] [15] [16] [17] [18] [19] [20] . Briefly, following the induction of inhalational anesthesia (isoflurane used with oxygen, induction 5%, maintenance 2.5%), T9 laminectomy was performed prior to impaction (online suppl. Fig. 1 ; for all online suppl. material, see www.karger.com/doi/10.1159/000475896). Sham control rats also underwent laminectomy without contusion. Manual bladder expression performed on each animal until bladder control was re-established. Representative images showing the extent of SCI via T9 laminectomy demonstrated in online supplementary Figure 1 .
Assessment of Functional Outcome
The functional neurological deficits due to cSCI were assessed by Basso, Beattie, and Bresnahan (BBB) behavioral analysis [21] . Animals were observed individually in an open field testing area consisting of an unfilled plastic wading pool and the BBB scores recorded by a single blinded reviewer either on post-impaction days 0 through 18 post-cSCI (mid phase) or on days 0, 2, 7, 14, 21, 28, 35, and 42 (late phase). Baseline measurements were taken the day before starting treatments.
Assessment of Thermal Hyperalgesia
Thermal hyperalgesia (TH) testing developed by Hargreaves et al. [22] was used to assess the animal's withdrawal of a hind paw to a thermal noxious stimulus. We have adopted and established this as a sensitive and reliable behavior test as reported previously in several studies [13] [14] [15] [16] [17] [18] [19] [20] . Briefly, animals were placed inside the Ugo Basile Plantar Test apparatus (Plantar TM Test, Stoelting, IL, USA) having a focused beam of radiant heat underneath their paws. When each animal moved its paw, a photocell turned off the heat, and the latency to withdraw the paw was recorded. Strength of stimulation was adjusted to produce baseline latencies of 8-10 s (typically 45-47 ° C). In our standardized TH model, we have found that a decreased withdrawal latency greater than 2-3 s compared to the baseline is an indicator of NP. A safety cutoff of 15 s was used to prevent prolonged exposure to the noxious heat. Hind limb TH testing was performed the day prior to injury and then again on post-injury days 18, 21, 28, 35, and 42. Animals were killed at different experimental time points following injury and the spinal cord harvested for molecular analysis.
Spinal Cord Harvest
Animals were euthanized on days 18 and 42 following injury, and their spinal cords were harvested for MMP2 expression analysis.
Western Blot Analysis
The spinal cord tissue samples from the epicenter of the injury were lysed in lysis buffer (Sigma Chemical Co., St. Louis, MO, USA) and the protein content determined by Lowry's method [23] . The tissue samples (30 μg/lane) and pre-stained molecular mass markers (Bio-Rad, Hercules, CA, USA) were denatured in SDS reducing buffer (1: 2 by volume, Bio-Rad, Hercules, CA, USA) and electrophoresis performed using 12.5% tris-HCl gels (Biorad, Hercules, CA, USA). The resolved proteins were then transferred to a polyvinylidene difluoride membrane (PVDF, 0.2 μm; Bio-Rad, Hercules, CA, USA) and incubated in 5% non-fat dry milk in trisbuffered saline (TBS) for 30 min. The blot was then incubated overnight at 4 ° C with polyclonal antibody against MMP2 (H-76, 1: 500; Santa Cruz Biotechnology, Inc.). The blot was then rinsed in TBS and incubated with corresponding horseradish peroxidaseconjugated secondary IgG (1: 2,000; Santa Cruz Biotechnology, CA, USA) for 1.5 h at room temperature. Bound antibody was visualized using the enhanced chemiluminescent solution (Pierce, Thermo Fisher Scientific, Rockford, IL, USA) as per the manufacturer's instructions. The chemiluminescent signal was captured on autoradiographs (Eastman Kodak, Rochester, NY, USA) and scanned. The signal's intensity (including a blank region) was quantitated using the NIH Image J software. The immunoblot was treated in stripping buffer (Pierce, Thermo Fisher Scientific, Rockford, IL, USA) for 30 min and then re-probed with a mouse monoclonal antibody against β-actin (1: 4,000; Sigma, St. Louis, MO, USA) to quantitate the expression of β-actin. Control and treatment values were corrected for blank values and normalized to their respective β-actin band intensity.
Statistical Analysis
Descriptive statistics, including means and SDs for continuous variables and frequencies for categorical variables, were calculated for FA and water groups. For the BBB pain score experiments, analyses were performed both cross-sectionally and longitudinally. In particular, we used a linear mixed effects model to assess how each individual animal progressed over the course of treatment. In addition, in assessing TH testing of injured animals treated with FA and water, a simple t test (paired or 2-sample) was performed when such methods were appropriate and informative. For MMP2 experiments, a one-way analysis of variance model was utilized, where the null hypothesis that the group means of sham, control (water), and FA treatments are equal is tested globally. We investigated how well the model fits the data by reporting goodness-offit statistics, including R-squared measures, which describe the percentage of variation in the response that is explained by the model. Finally, we performed post-hoc analysis to assess the effects of pairwise comparisons between the groups (i.e., water vs. sham, FA vs. sham, and FA vs. water), using Tukey's honestly significant difference post-hoc test. All statistical analyses were performed using the 2-sided alpha significance level of 0.05, with STATA version 14 software.
Results
Locomotor Functional Recovery in Spinal Cord-Injured Animals Treated with FA
To determine whether FA administration after SCI improves function, we performed BBB scoring on injured animals treated with 80 μg/kg FA or with water for 3 days prior to injury and 17 days post cSCI. BBB scores obtained on a daily basis from days 0 to 18 post cSCI were analyzed using linear regression models. These analyses show highly significant differences between the FA and the water groups ( Fig. 1 a) . BBB scores were also collected on days 0, 7, 14, and 18 post cSCI. The analysis of these data showed significant differences between water (control) and FA groups over time ( Fig. 1 b) . In a separate experiment, we injected the animals on a daily basis 3 days before and 14 days after injury, and the BBB scoring was done from day 0 through 42 days' post cSCI (on days 0, 2, 7, 14, 21, 28, 35, and 42). The analysis of the data with a 2-sample t test with equal variances assumption showed an overall statistically significant difference in BBB scores between animals on FA and those on water ( Fig. 1 c) . Together, these data show that FA improves locomotor function during both the mid phase and the late phase of injury.
Decreased NP in Spinal Cord-Injured Animals Treated with FA
To determine whether FA administration after SCI decreases NP, we tested TH on injured animals treated with 80 μg/kg FA or with water, for 3 days prior to injury and 17 days post cSCI. The TH was measured on day 18 post cSCI. The results show significant differences between FA and control (water) groups, indicating that FA ameliorates NP after SCI ( Fig. 2 a) . To determine whether FA administration after SCI decreases NP for a prolonged period of time, we tested TH on injured animals treated with 80 μg/kg FA or water for 3 days prior to injury and 14 days post cSCI on days 21, 28, 35, and 42. A paired t test of pain response by each of those groups revealed a highly statistically significant difference between FA-and water-treated groups on days 21, 28, and 35 ( Fig. 2 b) . We also ran a mixed effect linear regression model that included treatment groups and time and in which the outcome is pain response so that we could investigate the pain responses of an animal in the FA group compared to the same type of animal in the water group -the inferences in our model were made about the animals in our groups rather than based on a population average. The correlations among responses for each individual animal arose from natural heterogeneity in regression coefficients across all the animals. In addition, we also tested if there is an interaction between treatment and time. The results show that animals in the FA-treated group responded 1.22 times higher for every unit increase in pain than a similar animal given water treatment and that there is no interaction between treatment and time; time is consistent with the profile plot ( Fig. 2 bii) . Overall, the data show a higher response in the FA group compared to the water group. On the other hand, there is no statistical difference between the FA-and water-treated groups on day 42 ( Fig. 2 c) owing to the recovery during that time period.
Decreased MMP2 Expression in Spinal Cord-Injured Animals Treated with FA
To determine whether FA administration altered MMP2 expression, we tested MMP2 expression in spinal cord epicenter tissue from injured animals treated with 80 μg/kg FA or with water for 3 days prior to injury and 17 days post cSCI. Western blot results from tissues harvested on day 18 or 42 post cSCI show significant decrease in MMP expression in tissues from injured animals treated with 80 μg/kg FA compared to the control (water; Fig. 3 ai, ii and bi, ii).
Discussion
MMPs are endopeptidases known to play a role in the extracellular matrix degradation, immune response, pathogenesis, inflammation, cellular signaling, cell migration, tissue remodeling, and repair [24] [25] [26] . MMP induction following injury [27] is known to limit functional recovery after SCI [28] . MMPs have been reported to cause inflammation and NP after peripheral nerve injury [1] . Several studies have shown a relationship between DNA methylation and MMP expression and NP after CNS injury [6, 29, 30] . Here, in this paper, we show the effect of FA, a dietary supplement and key methylator of the CNS, on the expression of MMP2. Our results show that FA alters the expression of MMP2, alleviates NP, and improves functional recovery after cSCI. This opens up a novel therapeutic avenue for managing SCIinduced NP and might throw light on a possible epigenetic mechanism in FA-induced recovery after SCI.
This study shows that MMP2 expression is significantly reduced by FA treatment 3 days pre-cSCI and 17 days Earlier studies have shown that FA induces spinal axon regeneration and improves functional recovery after SCI partly via DNA methylation [11, 12] . Studies have shown that intrathecal administration of DNA methyltransferase inhibitor following CCI results in the suppression of global increase in DNA methylation and MeCP2, alleviating mechanical allodynia and TH [6] . In this respect, the promoter region of 13 of 24 MMPs shows CpG islands with a potential for epigenetic regulation by methylation [29] . Methylation contributes to the transcriptional activity of the MMP9 promoter, and the hypomethylation of MMP3 results in increased protein expression [30] . The role of FA in MMP2 methylation needs to be investigated further. TH was decreased on day 18 post cSCI, which followed FA administration 3 days prior to cSCI and 17 days post cSCI ( Fig. 2 a) . However, there is no significant difference in TH latency in FA-treated and control groups when ob- served on day 42 ( Fig. 2 b) . We have demonstrated previously that animals exhibiting elevated TH on days 21 and 28 post cSCI had higher levels of MMP2 in the injured spinal cord, as compared to those animals not exhibiting TH [5] . By lowering MMP2 expression, possibly by methylation with FA, we anticipate a reduced incidence of TH. We hypothesize that ongoing methylation may be necessary to achieve effects on TH. Other factors effecting MMP2 expression such as TIMP1 and TIMP3 are also targets for further research. Regeneration of axons following CNS injury is inhibited by the formation of a glial scar and immature astrocytes. MMP2 has been reported to facilitate immature astrocytes to cross the proteoglycan rim across the immature glial bridges following use of 13 selective enzyme inhibitors [31] . It is also known that MMPs are integral to the formation of inhibitory glial scar and cytoskeleton-mediated astrocyte migration [32] . Experimental models of SCI suggest that MMP9 supports infiltration of inflammatory cells into the injured spinal cord and most likely contributes to early disruption of the blood-spinal cord barrier [28] . The spinal cord in response releases MMP9, initiating the aforementioned macrophage infiltration and degradation of myelin basic protein. Resulting exposure of the bare axon leads to increased sodium channel expression and ectopic hyperexcitability of afferent neurons, resulting in action potentials outlasting the stimulus that creates central sensitization, a common mechanism of NP after CNS injury [33] . However, our expression studies on MMP9 in injured spinal cords from animals treated with FA in the acute phase of injury (on days 1, 3, and 7 post cSCI) showed no significant difference from controls (data not shown). This might be attributed to a shorter FA treatment regimen used in this study or may be a result of a different transcriptional mechanism of MMP9 that is independent of folate. In this context, the contribution of FA to curb these mechanisms by mechanisms other than DNA methylation is yet another topic for further investigation.
The implications of FA supplementation in stimulating notch signaling, cell proliferation, and differentiation of neural stem cells have been reported [34, 35] . Underlying mechanisms revealed a significant upregulation of Notch1 mRNA and protein expression, decline in expression of inflammatory proteins in nerve cells under hypoxia condition by preventing Ca 2+ overload, and protective effect on nerve cells. Furthermore, a combination therapy of FA administered with adult neural stem cells resulted in a significantly improved nerve function by sustaining microenvironment homeostasis in the neurons of SCI rats [36] .
Conclusions
The experiments described in this paper allowed us to partially define the role of MMP2 in NP and will serve as a foundation for further experiments. Use of dietary supplement FA to induce epigenetic modification of MMPs may be a novel therapeutic approach for dealing with NP after injury. This study will pave the way for follow-up clinical testing of the dietary supplement FA with current therapies to reduce patients suffering from SCI-induced NP.
